BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 15850909)

  • 1. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
    Dinniwell R; Lock M; Pintilie M; Fyles A; Laframboise S; Depetrillo D; Levin W; Manchul L; Murphy J; Oza A; Rosen B; Sturgeon J; Milosevic M
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):104-10. PubMed ID: 15850909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.
    Rochet N; Sterzing F; Jensen AD; Dinkel J; Herfarth KK; Schubert K; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1382-9. PubMed ID: 19628341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
    Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
    Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
    Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
    Lupe K; Kwon J; D'Souza D; Gawlik C; Stitt L; Whiston F; Nascu P; Wong E; Carey MS
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):110-6. PubMed ID: 17084542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
    Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP
    Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
    Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI
    Cancer; 2006 Sep; 107(6):1321-30. PubMed ID: 16902985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group.
    Bamias A; Deliveliotis Ch; Fountzilas G; Gika D; Anagnostopoulos A; Zorzou MP; Kastritis E; Constantinides C; Kosmidis P; Dimopoulos MA
    J Clin Oncol; 2004 Jun; 22(11):2150-4. PubMed ID: 15169801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of progression-free interval in patients with ovarian cancer treated by first-line chemotherapy with paclitaxel and carboplatin].
    Lehoczky O; Pulay T
    Magy Onkol; 2005; 49(4):315-8. PubMed ID: 16518475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and carboplatin as outpatient therapy for stage III and IV epithelial ovarian cancer.
    Balbi GC; Menditto A; Calabria G; Musone R; Di Prisco L; Cassese E; Balbi C; Cardone A
    Panminerva Med; 2001 Dec; 43(4):263-5. PubMed ID: 11677421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
    Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.